- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT03740126
Surveillance With PET/CT and Liquid Biopsies of Stage I-III Lung Cancer Patients After Completion of Definitive Therapy (SUPE_R)
Surveillance With PET/CT and Liquid Biopsies of Stage I-III Lung Cancer Patients After Completion of Definitive Therapy; a Randomized Controlled Trial
연구 개요
연구 유형
등록 (실제)
단계
- 해당 없음
연락처 및 위치
연구 장소
-
-
-
Copenhagen, 덴마크, 2100
- Rigshospitalet
-
Gentofte, 덴마크, 2900
- Gentofte Hospital
-
Herlev, 덴마크, 2730
- Herlev Hospital
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Patient with non-small cell lung cancer (NSCLC), proven by cytology or histology
- Patient in clinical stages I-III
- Age≥ 18 years
- Performance status ≤ 2 at the time of referral to therapy
- Patient referred for definitive treatment (e.g. surgery, surgery followed by adjuvant chemotherapy, concomitant radio-chemotherapy, conventional or stereotactic radiotherapy or radiofrequency ablation).
- Patient has given his/her written informed consent before any specific procedure from protocol
Exclusion Criteria:
- Patient, whose disease has progressed within the first 3 months after cancer treatment, e.g. confirmed progressive disease on CT.
- Persons deprived of liberty or under guardianship or curators
- Dementia, mental alteration, severe psychiatric disease or other circumstances that can compromise informed consent from the patient and/or adherence to the protocol and the monitoring of the trial
- Pregnant or breastfeeding women
- Patient participating in another interventional study during the surveillance period. This is only relevant for studies that might interfere with the intervention, whereas studies on late effects will not preclude participation in SUPE-R. Participation in protocols related only to initial treatment will not preclude participation in SUPE-R. Cases of doubt will be settled by the steering committee.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 특수 증상
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
---|---|
실험적: Arm A, PET/CT
18F-2-fluoro-2-deoxy-D-glucose fluorodeoxyglucose positron emission tomography with computed tomography (FDG PET/CT) replacing computed tomography (CT) at months 6, 12, 18 and 24, otherwise as B with CT scan months 9, 15 and 21.
Quality of life assessment and liquid biopsy every 3 months for later analysis.
|
In the experimental arm (A), an FDG-PET/CT scan will replace the CT-scan at 6, 12, 18 and 24 months post-treatment.
A standard CT-scan will be performed at 3, 9, 15 and 21 months post-treatment.
All patients will be asked for a blood sample for liquid biopsy and to fill in a quality of life questionnaire, concurrently every 3 months.
|
간섭 없음: Control arm B
CT-scan and clinical evaluation every 3 months.
Quality of life assessment and liquid biopsy at every 3 months for later analysis.
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Number of relapses treatable with curative intent
기간: Until first detected relapse or 2 years after enrollment
|
As decided by multidisciplinary meetings
|
Until first detected relapse or 2 years after enrollment
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Time to verified relapse
기간: From date of randomization until the date of first documented relapse assessed up to 24 months
|
Relapse verified by histology or imaging combined with MDM review
|
From date of randomization until the date of first documented relapse assessed up to 24 months
|
Overall survival
기간: From date of randomization until the date of censoring or death from any cause, whichever came first, assessed up to 36 months
|
Death of any course or censoring
|
From date of randomization until the date of censoring or death from any cause, whichever came first, assessed up to 36 months
|
Overall survival for patients with relapse
기간: From randomization until 12 months after first detected relapse or until death (whichever comes first)
|
Death of any course or censoring
|
From randomization until 12 months after first detected relapse or until death (whichever comes first)
|
Performance status at relapse
기간: From randomization until first detected relapse or 24 months
|
Performance status of study participants at relapse will be assessed using Eastern Cooperative Oncology Group (ECOG) performance status scale from grade 0 to grade 4, where grade 0 corresponds to a patient who is "fully active, able to carry on all pre-disease performance without restriction" and grade 4 is a patient who is "completely disabled; cannot carry on any selfcare; totally confined to bed or chair".
|
From randomization until first detected relapse or 24 months
|
Quality of life / QLQ-C30
기간: From randomization until first detected relapse or 24 months
|
Quality of life will be assessed every 3rd month using a validated questionnaire, European Organisation for Research and Treatment of Cancer Quality of Life Questionaire Core Questionaire 30 (EORTC QLQ-C30). The questionaire is filled out by study participants at each control visit and patients score severity of a range of symptoms during the past week on a scale of 1 ("Not at all") to 4 ("Very much"). |
From randomization until first detected relapse or 24 months
|
Quality of life / QLQ-LC13
기간: From randomization until first detected relapse or 24 months
|
Quality of life will be assessed every 3rd month using a validated questionnaire, European Organisation for Research and Treatment of Cancer Quality of Life Questionair Lung Cancer 13 (EORTC QLQ-LC13). The questionaire is filled out by study participants at each control visit and patients score severity of a range of symptoms during the past week on a scale of 1 ("Not at all") to 4 ("Very much"). |
From randomization until first detected relapse or 24 months
|
Quality of life / Raw score
기간: From randomization until first detected relapse or 24 months
|
From the results of QLQ-C30 and QLQ-LC13 a Raw Score (RS) is calculated (average of all scores) and Quality of Life is calculated as (RS - 1)/3 which outputs a value between 0 and 1, where 0 is a complete absence of symptoms and 1 is the maximum severity of all related symptoms.
This will be used for calculation of QALY in the cost-effectiveness analysis.
|
From randomization until first detected relapse or 24 months
|
Number of procedures to assess incidental findings
기간: From randomization until 24 months or first detected relapse or until death (whichever comes first)
|
Procedures resulting from an incidental finding on a follow up scan
|
From randomization until 24 months or first detected relapse or until death (whichever comes first)
|
Types of procedures to assess incidental findings
기간: From randomization until 24 months or first detected relapse or until death (whichever comes first)
|
Invasive / non-invasive
|
From randomization until 24 months or first detected relapse or until death (whichever comes first)
|
Adverse events due to invasive procedures done to assess incidental findings
기간: From randomization until 24 months or first detected relapse or until death (whichever comes first)
|
For example: Bleeding, pneumothorax, hospital admission
|
From randomization until 24 months or first detected relapse or until death (whichever comes first)
|
Cost-effectiveness analysis of intervention
기간: From randomization until 24 months or 12 months after first detected relapse or until death (whichever comes first)
|
Cost-effectiveness of the PET/CT regimen vs the CT regimen is assessed with the ICER (incremental cost-effectiveness ratio), i.e. the ratio of net health care costs to net QALYs ( quality-adjusted life years).
Net health care costs are estimated as the health care costs difference between the two arms and net QALYs likewise.
Health care costs are calculated from register-based information on health care consumption cumulated in 2-yrs follow-up (DRG-rates) supplemented by intervention costs based on project costs.
The relevant cost data are available at "Sundhedsdatastyrelsen" using their research service.
|
From randomization until 24 months or 12 months after first detected relapse or until death (whichever comes first)
|
Type of treatment after verification of relapse
기간: From randomization until 12 months after first detected relapse or until death (whichever comes first)
|
Description of treatment - e.g.
surgical, radiotherapy, stereotactic ablative body radiotherapy, medical treatment
|
From randomization until 12 months after first detected relapse or until death (whichever comes first)
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Barbara M Fischer, MD PhD DMSci, Rigshospitalet, Denmark
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (예상)
연구 완료 (예상)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- H-18009536
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
암종, 비소세포폐에 대한 임상 시험
-
Millennium Pharmaceuticals, Inc.완전한GCB(Non-Germinal B-cell-like) 미만성 거대 B-세포 림프종(DLBCL)미국
Whole body 18F-FDG PET/CT에 대한 임상 시험
-
Fifth Affiliated Hospital, Sun Yat-Sen University모병
-
Peking University Cancer Hospital & Institute알려지지 않은
-
Peking Union Medical College Hospital모집하지 않고 적극적으로
-
University of Lausanne HospitalsGeorge Coukos, MD PhD, Head of oncology모병
-
Washington University School of Medicine종료됨